Relevant bibliographies by topics / Chemotherapy of cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Chemotherapy of cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chemotherapy of cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chemotherapy of cancer"

1

Armini, Ni ketut alit, Masfin Muhayanah, and Aria Nastiti. "DIARRHEA INCIDENT IN CERVICAL CANCER PATIENTS POST CHEMOTHERAPY TREATMENT." Jurnal NERS 11, no. 1 (April 1, 2016): 106. http://dx.doi.org/10.20473/jn.v11i12016.106-111.

Full text
Abstract:
Backgrounds : Cervical cancer is second most diseases suffered by women. Chemotherapy is primary treatment for cervical cancer. Chemotherpy has some side effect, and one of them is diarrhea. Diarrhea make cervical cancer suffered more. The purpose of this research was to analyze the correlation of factor’s that cause diarrhea on cervical cancer.Methods : This research uses descriptive analitic method with retrospective design. The population in this research is all patients who had post first chemotherapy. Sample in this study were 21 respondents, with purposive sampling. Variable independent were type of chemotherapy drugs, character of chemotheraphy, staging, stress and dietary. Variable dependent was diarrhea. Data collected using quesionare. Data were analyzed using chi square test with level of significant α≤0,05.Results : The result of the study reveals that type of the chemotherapy drug p:0,598, character of chemotheraphy p:0,336,. Staging has correlation with diarrhea significant of p:0,022. Stress and dietary analysisis presented p:0,00. It means that there was significant correlation with diarrhea.Conclusion : It can be concluded that diarrhea incident related to staging, stress and dietarry. There‘s no correlation between type of chemotherapy drug, character of chemotheraphy with diarrhea Further studies should give health education about dietary causing diarrhea, chemotherapy procedural and sides effect’s, increase supports for patient with cervical cancer. Keyword: Cervical Cancer, Chemotherapy, Diarrhea.
APA, Harvard, Vancouver, ISO, and other styles
2

Jacobs, Charlotte. "Cancer chemotherapy." International Journal of Radiation Oncology*Biology*Physics 12 (November 1986): 78. http://dx.doi.org/10.1016/0360-3016(86)90477-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gudas, Stephen A. "Cancer Chemotherapy." Rehabilitation Oncology 13, no. 2 (1995): 12–20. http://dx.doi.org/10.1097/01893697-199513020-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kardinal, Carl G. "Cancer chemotherapy." Postgraduate Medicine 77, no. 6 (May 1985): 165–74. http://dx.doi.org/10.1080/00325481.1985.11698989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shalaby, Waleed S. W., Heidi J. Gray, and John J. Mikuta. "Cancer Chemotherapy." Postgraduate Obstetrics & Gynecology 24, no. 13 (June 2004): 1–7. http://dx.doi.org/10.1097/00256406-200406300-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Anderson, Philip O. "Cancer Chemotherapy." Breastfeeding Medicine 11, no. 4 (May 2016): 164–65. http://dx.doi.org/10.1089/bfm.2016.0042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zeller, John L. "Cancer Chemotherapy." JAMA 299, no. 22 (June 11, 2008): 2706. http://dx.doi.org/10.1001/jama.299.22.2706.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Owen, L. "Cancer chemotherapy." Veterinary Record 118, no. 13 (March 29, 1986): 364–66. http://dx.doi.org/10.1136/vr.118.13.364.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Berman, Arlene, Laura Chisholm, Maria de Carvalho, Joan A. Piemme, and Catherine Rice Gorrell. "Cancer Chemotherapy." Cancer Nursing 16, no. 2 (April 1993): 145???160. http://dx.doi.org/10.1097/00002820-199304000-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chisholm, Laura G., Arlene R. Berman, Maria de Carvalho, and Catherine Rice Gorrell. "Cancer Chemotherapy." Cancer Nursing 16, no. 3 (June 1993): 237???246. http://dx.doi.org/10.1097/00002820-199306000-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Chemotherapy of cancer"

1

Bates, Robert W. "Prodrugs for cancer chemotherapy." Thesis, University of Oxford, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.333294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Prytz, Anna, and Linda Harnfeldt. "Chemotherapy and Cancer - childrens experiences." Thesis, Kristianstad University College, Department of Health Sciences, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-3754.

Full text
Abstract:

With good knowledge about the disease and the treatment, the fear and worry of children and parents can be reduced. Children may be helped by painting to express their experiences. In order to have a good care, the care-personnel need to see and understand what the children need. It is important to live an as regular life as possible during the disease and its treatment. The aim of this study was to elucidate how children experience chemotherapy in conection with their cancer disease. The method that was chosen was an systematic literature review. The result was based on five qualitative articles, which could be divided into four categories: to feel afraid and worried, to feel limited, to feel different and to feel sick. Discussion: There is risk that important information that the children want to tell will go lost when parents and care-personnels communicate children’s experiences to a third part. There is reaserch telling that children may need an adult to help express their experiences.

APA, Harvard, Vancouver, ISO, and other styles
3

Sujendran, Vijay. "Neoadjuvant chemotherapy in oesophageal cancer." Thesis, University of East Anglia, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501118.

Full text
Abstract:
Neoadjuvant chemotherapy in oesophageal cancer has gained rapid favour in le United Kingdom over the past few years. It remains controversial outside the UK, with mixed results from clinical trials. The work in this thesis begins with a review of the literature on neoadjuvant chemotherapy, and of the antimetabolites and platinum agents used. The quantitative reverse transcriptase polymerase chain reaction (qRTPCR) used to identify molecular determinants of chemosensitivity is discussed followed by a look at the clinical experience of neoadjuvant chemotherapy at a single centre. Over the past six years 194 patients in Oxford have undergone neoadjuvant chemotherapy with cisplatin and 5-flurouracil. Six patients developed progressive disease, 12 patients stopped chemotherapy early, one patient died during chemotherapy and one patient had perforation of the oesophagus. Overall chemotherapy was well tolerated among patients with no significant increase in respiratory complications and anastomotic leak following the use of neoadjuvant chemotherapy. Following the advent of neoadjuvant chemotherapy, there has been a significant decrease in circumferential resection margin involvement, compared to historical controls. Locoregional recurrence and overall survival have also improved. Cox's multivariate analysis shows circumferential resection margin to be an independent prognostic factor for locoregional recurrence and overall survival.
APA, Harvard, Vancouver, ISO, and other styles
4

Miles, Philip James. "Metal complexes for cancer chemotherapy." Thesis, University of Manchester, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.627992.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Taylor, W. B. "Control of emesis in cancer chemotherapy." Thesis, University of Newcastle upon Tyne, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.378877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vacchelli, Erika. "Immunogenetic determinants of chemotherapy response in cancer." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T041.

Full text
Abstract:
L’efficacité de la chimiothérapie contre la croissance tumourale repose sur l'induction d'une mort des cellules tumourales dite immunogène. Les cellules tumourales mourantes agissent alors comme un vaccin thérapeutique en stimulant une réponse immunitaire anti-tumourale capable de contrôler, voire d'éliminer, les cellules cancéreuses résiduel. Les trois marqueurs principales de la mort cellulaire immunogène (MCI), sont (i) l'exposition pré-apoptotique de la calréticuline (CRT) à la surface des cellules, (ii) la sécrétion de l'ATP pendant l'apoptose qui dépend du processus d'autophagie, et (iii) le relargage post-apoptotique de la protéine non-histone de fixation à la chromatine HMGB1 (High Mobility Group B1). CRT, ATP et HMGB1 se lient respectivement à CD91, au récepteur purinergique P2RX7 (Purinergic Receptor P2X, ligand-gated ion channel 7) et au récepteur TLR4 (Toll-like Receptor 4) situés à la surface des cellules dendritiques. En retour, ces interactions initient respectivement la phagocytose des cellules mourantes, la production de l'interleukine-1β et la cross-présentation des antigènes tumouraux aux lymphocytes T.Notre laboratoire a précédemment démontré que la chimiothérapie adjuvante présente une efficacité réduite chez des patients atteints de cancers colorectaux et du sein portant un polymorphisme d'un seul nucléotide ou SNP (Single-Nucleotide Polymorphism) compromettent la fonction des gènes P2RX7 et TLR4, notamment rs3751143 (496Glu>Ala) pour le gène P2RX7 et rs4986790 (299Asp>Gly) pour le gène TLR4.Compte tenu des ces résultats que mettent en évidence la relation étroite entre l’efficacité de la chimiothérapie anticancéreuse et un système immunitaire opérationnel, nous avons décidé d'étudier l'effet de ces SNPs, soit sur la survie globale soit sur la survie sans événement, chez des patients atteints de cancer pulmonaire non à petites cellules ou NSCLC (Non-Small Cell Lung Carcinoma) et de cancers de la tête et du cou ou HNSCC (Head and Neck Squamous Cell Carcinoma). De plus, nous avons porté notre attention sur un autre SNP affectant le gène ATG16L1 (Autophagy-related 16-Like 1), notamment rs2241880 (300Thr>Ala) qui compromet l’activité d’un gène fondamental dans le processus d’autophagie.Dans les cancers NSCLC, les allèles mutants "perte de fonction" des gènes ATG16L1, P2RX7 et TLR4 n'affectent pas la survie globale, indépendamment du type de chimiothérapie administrée. Au contraire, les patientes atteintes de HNSCC, portant au moins un allèle "perte de fonction" d’ATG16L1 et TLR4, présentent un taux de survie sans récidive inferieure par rapport aux patients qui présentent un genotype sauvage. Ce travail décrit pour la première fois un biomarqueur prognostique pour ce type de cancer.De plus, nous avons pu définir, par génotypage à haut débit, une signature de SNPs prédictive de la réponse à la chimiothérapie neoadjuvantes à base d'anthracyclines et des taxanes chez les patients atteints de cancer du sein. En particulier, la combinaison des deux paramètres clinicopathologiques classiques (âge lors du diagnostic et récepteur aux œstrogènes) avec les génotypes rs1076669 du gène ECE1 (Endothelin Converting Enzyme 1; 341Thr>Ile) et rs2277413 du gène PZP (Pregnancy-Zone Protein; 813Val>Ala) a permis de définir trois grandes catégories des patients et leur probabilité respective d'atteindre la réponse complète pathologique après traitement.L'identification de nouveaux biomarqueurs associés à une absence/diminution de réponse à la chimiothérapie apparaît critique pour choisir des alternatives thérapeutiques appropriées et éviter les effets secondaires indésirables chez les non-répondeurs
Successful chemotherapeutics can induce a type of tumour cell death that is immunogenic, implying that patient’s dying cancer cells function as a therapeutic vaccine and elicit an anti-tumour immune response that controls the residual disease. The three main hallmarks of immunogenic cell death (ICD) are the pre-apoptotic exposure of calreticulin (CRT) on the cell surface, the autophagy-dependent secretion of ATP during the blebbing phase of apoptosis and the post-apoptotic release of the chromatin-binding non-histone protein high mobility group B1 (HMGB1). CRT, ATP and HMGB1 interact with CD91, purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) and Toll-like receptor 4 (TLR4), respectively, on the surface of dendritic cells (DCs), thus promoting the engulfment of dying cells, the production of IL-1β and the cross-presentation of tumour-associated antigens to T cells, respectively.Our laboratory has demonstrated that adjuvant chemotherapy exhibits a reduced efficacy in breast and colorectal cancer patients bearing single-nucleotide polymorphisms (SNPs) that compromise the function of P2RX7 or TLR4, such as rs3751143 in P2RX7 (Glu496Ala) and rs4986790 in TLR4 (Asp299Gly).Driven by these results, underpinning the intimate relationship between the success of anti-cancer chemotherapy and an operational immune system, we decided to investigate the effect of these SNPs on disease outcome among non-small cell lung carcinoma (NSCLC) and head and neck squamous cell carcinoma (HNSCC) patients. Additionally, we focused our attention on a SNP in autophagy related 16-like 1 (ATG16L1), namely rs2241880 (Thr300Ala), which compromises the activity of one pivotal autophagic gene. In NSCLC patients, loss-of-function ATG16L1, P2RX7 and TLR4 alleles do not affect overall survival, irrespective of the administration and type of chemotherapy. Conversely, HNSCC patients bearing at least one loss-of-function ATG16L1 or TLR4 allele exhibit a reduced disease-free survival when compared to their wild-type counterparts. This is the first report highlighting a putative prognostic biomarker for this malignancy. Furthermore, taking advantage of a high throughput genotyping study, we delineated a SNP-based signature that predicts the response of breast cancer patients to anthracycline- and taxane-based neoadjuvant chemotherapy. Particularly, the combination of two classical clinicophatological parameters (age at diagnosis and estrogen receptor) and genotype at the ECE1 (rs1076669 Thr341Ile) and PZP (rs2277413 Val813Ala) loci allowed us to define three broad categories with a correspondent probability of achieving pathological complete response. The identification of new biomarkers associated with a reduced/absent response to chemotherapy appears critical for selecting appropriate therapeutic alternatives, and avoiding undesired side effects among non-responders
APA, Harvard, Vancouver, ISO, and other styles
7

Jackson, Trachette L. "Mathematical models in two-step cancer chemotherapy /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/5730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sims, Margaret Alison. "Azoreductases in cancer therapy." Thesis, Open University, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.261397.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smit, Egbert Frederik. "Aspects of palliative chemotherapy for lung cancer." [S.l. : [Groningen : s.n.] ; University Library Groningen] [Host], 1990. http://irs.ub.rug.nl/ppn/292220588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaestner, Sabine Anna. "Studies on dose-banding of cancer chemotherapy." Thesis, University of Bath, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.438893.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Chemotherapy of cancer"

1

Priestman, Terry J. Cancer chemotherapy. 3rd ed. London: Springer-Verlag, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Holmes, Susan. Cancer chemotherapy. London: Austen Cornish, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Society, Oncology Nursing. Cancer chemotherapy guidelines. Pittsburgh, Pa: Oncology Nursing Society, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

T, Bakowski Marie, and Hellmann K, eds. Chemotherapy of cancer. 3rd ed. New York: Wiley, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fischer, David S. Cancer chemotherapy handbook. 3rd ed. Chicago: Year Book Medical Publishers, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bardhan-Quallen, Sudipta. Chemotherapy. San Diego: Thomson/Gale, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Handbook of cancer chemotherapy. Philadelphia: Wolter Kluwer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fischer, David S. The cancer chemotherapy handbook. 4th ed. St. Louis: Mosby, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Council on Community Health, Hospital, Institutional, and Medical Affairs. Ad Hoc Committee on Protocol Development. Patients receiving cancer chemotherapy. Chicago, Ill: American Dental Association, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cancer chemotherapy: An introduction. 3rd ed. London: Springer-Verlag, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Chemotherapy of cancer"

1

Tohnai, Iwai, and Kenji Mitsudo. "Chemotherapy." In Oral Cancer, 319–33. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-54938-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lennan, Elaine. "Cytotoxic Chemotherapy." In Cancer and Cancer Care, 173–93. 1 Oliver’s Yard, 55 City Road London EC1Y 1SP: SAGE Publications Ltd, 2015. http://dx.doi.org/10.4135/9781473920620.n12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ratain, M. J., and R. B. Ewesuedo. "Cancer Chemotherapy." In Oncologic Therapies, 36–118. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-97988-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nakamura, Hideaki, and Hiroshi Maeda. "Cancer Chemotherapy." In Fundamentals of Pharmaceutical Nanoscience, 401–27. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9164-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bhandari, Prasan. "Cancer chemotherapy." In Pharmacology Mind Maps for Medical Students and Allied Health Professionals, 631–46. Boca Raton, FL : CRC Press/Taylor & Francis, 2020.: CRC Press, 2019. http://dx.doi.org/10.1201/9780429023859-73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Olive, D., and M. Peeters. "Chemotherapy." In Cancer in Children, 21–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-96889-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Frei, Emil. "Chemotherapy." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_1083-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Frei, Emil. "Chemotherapy." In Encyclopedia of Cancer, 956–60. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-46875-3_1083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Taguchi, Tetsuo. "Gastric Cancer." In Induction Chemotherapy, 163–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-18173-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Taguchi, Tetsuo. "Esophageal Cancer." In Induction Chemotherapy, 225–29. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28773-7_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chemotherapy of cancer"

1

Levine, M., A. Arnold, L. Kelleher, S. Lord, W. Hryniuk, J. Hrish, and M. Gent. "CANCER CHEMOTHERAPY AND THROMBOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643203.

Full text
Abstract:
Malignant disease is recognized as a risk factor for venous thromboembolism. A number of recent reports have suggested that cancer chemotherapy may contribute to this risk, but it was not possible to separate the role of chemotherapy from the effects of the malignant disease. We are conducting a randomized trial to determine the optimal duration of adjuvant chemotherapy in women with Stage II breast carcinoma. These ambulatory patients, with negligible tumour burden, receive either 12 weeks of chemo-hormonal therapy (cyclophosphamide, methotrexate, 5 fluorouracil, vincristine, prednisone, adriamycin and tamoxifen) or 36 weeks of chemotherapy (cyclophosphamide, methotrexate, 5 fluorouracil, vincristine and prednisone). This study has provided us with an opportunity to evaluate the thrombogenic effects of chemotherapy since patients in the 12 week group, while off chemotherapy, can be compared directly to the patients in the other group who are still on chemotherapy. This allows the confounding influence of the malignant process to be circumvented. All patients undergo screening tests for thrombosis (impedance plethysmography and Doppler ultrasound) and routine clinical assessments. Suspected venous thrombosis is confirmed by venography and suspected pulmonary embolism by either pulmonary angiography or high probability ventilation perfusion scanning. There have been 11 episodes of venous thromboembolism to date among 191 patients of whom 164 have completed the first 36 weeks of study. There were 3 episodes in each group during the first 12 weeks. During the subsequent 24 weeks there have been no events in the group whose treatment was stopped and 5 events in the group still on treatment (p 0.03). These findings demonstrate that chemotherapy per se is an important risk factor for venous thromboembolism in patients with malignant disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Ramkumar, Barathram, and D. Subbaram Naidu. "Closed-Loop Optimal Control Strategy for Cancer Chemotherapy." In ASME 2007 International Mechanical Engineering Congress and Exposition. ASMEDC, 2007. http://dx.doi.org/10.1115/imece2007-43527.

Full text
Abstract:
Cancer chemotherapy is the treatment of cancer using drugs that kill the cancer cells, when the drugs are administered either orally or through veins. The drugs are delivered according to a schedule so that a particular dosage of drug level is maintained in the body. The disadvantage of these drugs is that they not only kill the cancer cells but also kill the normal healthy cells. The role of optimal control in chemotherapy is to maintain an optimum amount of drug level in the body so that only cancer cells are killed and hence the effect of drug on the healthy cells is minimized. Three different mathematical models for cancer growth are considered: log-kill hypothesis, Norton-simon model, and Emax model. Two different cost functions are considered for constrained and unconstrained optimal control, respectively. An open loop optimal control strategy has been reported in the literature. In this paper, a closed-loop optimal control strategy is addressed using all the three models and for both the cases of constrained and unconstrained drug delivery. For the unconstrained case the original nonlinear model has been linearized and the closed loop design is obtained by using matrix Riccati solutions. On the other hand, for the constrained case the original nonlinear model has been used to obtain closed loop optimal control using bang-bang strategy. Final simulation results show the advantages of closed loop implementation in terms of simpler and elegant controller design and incorporating the effect of current state variations.
APA, Harvard, Vancouver, ISO, and other styles
3

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685313.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated with 3 cycles of neoadjuvant chemotherapy and then taken up for interval debulking surgery (IDS) who had static or partial or complete response to chemotherapy. The remaining chemotherapy is delivered after the surgery. Patient who had limited disease had primary debulking surgery and then adjuvant chemotherapy according to institute protocol. Outcomes in terms of disease free and overall survival were analysed. Results: This retrospective analysis included 59 patients with limited disease who had primary debulking surgery and 283 patients with advanced disease who received neoadjuvant chemotherapy. The median age was 50 years and majority are in the 50-59 years age group. Age more than 60 years represent 14.5%. Postmenopausal women were55.3 % and premenopausal women were 44.7 %. Multiparity is higher 70.2% than the uniparity 16.4% ornulliparity 11.7%. Abdomen distension 42% and pain 25 % are the most common symptoms. Advanced stage was the most common presentation 71% with stage III-56.1% and stage IV-14.9%. Among the neoadjuvant chemotherapy group 126/283(44.5%) had optimal cytoreduction, 44/283 (15.5%) had suboptimal cytoreduction and 113/283 (40%) not suitable for IDS. The 5 year disease free and overall survival was 30.8% and 41.5% in the NACT group with advanced disease and 58.5% and 75.8% in the primary cytoreduction group who had limited diseaserespectively. The 5 years overall survival among the IDS group with optimal cytoreduction was 57.1% and 11.7% for the suboptimal cytoreduction group. The 5 years survival was not affected by the number of neoadjuvant chemotherapy cycles delivered before surgery in the IDS group. Patient who received paclitaxol + carboplatin as first line chemotherapy had better survival than carboplatin alone or cyclophosphamide + cisplatin. Conclusion: NACT as an alternative option to primary debulking surgery in operable EOC is still debatable. But for patient with high disease burden where optimal cytoreduction is not possible NACT strategy is a valid option. Recent randomised controlled trials from Europe had shown the noninferiority of neoadjuvant chemotherapy followed by IDS when compared to the primary debulking surgery in operable advanced EOC.
APA, Harvard, Vancouver, ISO, and other styles
4

R., Senthil J., Santa A., Pavan KB, Rakesh P., Pravanika G., Pravanika G., Narander Ch, and Krishna MMVT. "An Analysis of Acute Adverse Drug Reactions Occurring in Day Care Chemotherapy Setting in a Tertiary Care Cancer Centre." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735376.

Full text
Abstract:
Abstract Introduction Acute adverse drug reactions (ADRs) in day care chemotherapy are not uncommon and easily manageable many a time. However, sometimes they may lead to untoward events. It is of paramount importance to document and analyze such events in contemporary medical oncology practice for the best utilization and planning of available personnel and resources. Objectives This study was aimed to analyze the acute ADRs occurring in day care cancer chemotherapy setting. Materials and Methods All acute ADRs reported in day care cancer chemotherapy setting, during the administration of chemotherapy, at Basavatarakam Indo American Cancer Hospital, Hyderabad, Telangana, India, were included in the study from June 15, 2020 to September 30, 2020. The ADRs were classified in to anaphylactic, allergic, and gastrointestinal (nausea/vomiting/heart burns/chest tightness). All ADRs were graded according to CTCAE version 5.0. Suspected drugs, time to reaction, and corrective measures were analyzed. Results During the study period, a total of 8,600 sessions of day care chemotherapy were administered. ADRs were noticed in 83 cases (~1%). Among the reported ADRs, anaphylactic reactions were noted in 20 patients (24%); allergic reactions of grades 1 and 2 were noted in 41 patients (49%). Gastrointestinal ADRs were noted in 30 patients (36%). Adverse reactions are mostly seen in oxaliplatin (22.8%), rituximab (14.4%), paclitaxel (15.6%), carboplatin (13.2%), and docetaxel (7.2%). In grade-I (10%) and grade-II (63%) resections, supportive treatment was provided and chemotherapy was continued. Grade-III ADRs were noted in 21 patients (25%) out of whom, 3 patients required short-term intensive care, chemotherapy was withheld until the next cycle in one patient, and chemotherapy regimen was changed in 3 patients. No patient died of ADR. Conclusion Serious ADRs are rare in contemporary medical oncology practice during day care chemotherapy administration. Most acute ADRs were easily managed.
APA, Harvard, Vancouver, ISO, and other styles
5

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685312.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated with 3 cycles ofneoadjuvant chemotherapy and then taken up for interval debulking surgery (IDS) who had static or partial or complete response to chemotherapy. The remaining chemotherapy is delivered after the surgery. Patient who had limited disease had primary debulking surgery and then adjuvant chemotherapy according to institute protocol. Outcomes in terms of disease free and overall survival were analysed. Results: This retrospective analysis included 59 patients with limited disease who had primary debulking surgeryand 283 patients with advanced disease who recievedneoadjuvant chemotherapy. The median age was 50 years and majority are in the 50-59 years age group. Age more than 60 years represent 14.5%. Postmenopausal women were 55.3% and premenopausal women were 44.7 %. Multiparity is higher 70.2% than the uniparity 16.4% ornulliparity 11.7%. Abdomen distension 42% and pain 25% are the most common symptoms. Advanced stage was the most common presentation 71% with stage III-56.1% and stage IV-14.9%. Among the neoadjuvant chemotherapy group 126/283 (44.5%) had optimal cytoreduction, 44/283 (15.5%) had suboptimal cytoreduction and 113/283 (40%) not suitable for IDS. The 5 year disease free and overall survival was 30.8% and 41.5% in the NACT group with advanced disease and 58.5% and 75.8% in the primary cytoreduction group who had limited diseaserespectively. The 5 years overall survival among the IDS group with optimal cytoreduction was 57.1% and 11.7% for the suboptimal cytoreduction group. The 5 years survival was not affected by the number ofneoadjuvant chemotherapycycles delivered before surgery in the IDS group. Patient who received paclitaxol + carboplatin as first line chemotherapy had better survival than carboplatin alone or cyclophosphamide + cisplatin. Conclusion: NACT as an alternative option to primary debulking surgery in operable EOC is still debatable. But for patient with high disease burden where optimal cytoreduction is not possible NACT strategy is a valid option. Recent randomised controlled trials from Europe had shown the noninferiority of neoadjuvant chemotherapy followed by IDS when compared to the primary debulking surgery in operable advanced EOC.
APA, Harvard, Vancouver, ISO, and other styles
6

Riah, Rachid, Mirko Fiacchini, and Mazen Alamir. "Invariance-based analysis of cancer chemotherapy." In 2015 IEEE Conference on Control Applications (CCA). IEEE, 2015. http://dx.doi.org/10.1109/cca.2015.7320761.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Claver, Jimbo Henri, and Isidore Seraphin Ngongo. "Modelling Cancer Chemotherapy with Side-effects." In Environment and Water Resource Management / 837: Health Informatics / 838: Modelling and Simulation / 839: Power and Energy Systems. Calgary,AB,Canada: ACTAPRESS, 2016. http://dx.doi.org/10.2316/p.2016.838-010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bae, Sun-Hee, and Young-Sun Park. "Emotion of Cancer Patients Undergoing Chemotherapy." In Healthcare and Nursing 2016. Science & Engineering Research Support soCiety, 2016. http://dx.doi.org/10.14257/astl.2016.132.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sarmento, Carlos Eduardo, Daniel Guerra, Deborah Dantas, Emanuel Arnaud, Hallysson Santos, João Pedro Dias, Matheus Andrade, and Alyson Souza. "POSTER: Dagda - A Virtual Reality Experience for Pediatric Patients with Cancer in Chemotherapy." In XXI Symposium on Virtual and Augmented Reality. Sociedade Brasileira de Computação - SBC, 2019. http://dx.doi.org/10.5753/svr_estendido.2019.8467.

Full text
Abstract:
During the process of chemotherapy of pediatric patients with cancer, the discomfort proves to be one of the many challenges for the patient, intensified by the ease at which the child becomes upset or annoyed. As a form of distraction during part of the treatment, this poster proposes an application of virtual reality to mask the process, and additionally, allows for association within the cancer patient’s situation
APA, Harvard, Vancouver, ISO, and other styles
10

Ruiz, M. A., I. Marugán, A. Estellés, F. Espafia, J. Aznar, and J. García-Conde. "THE INFLUENCE OF CHEMOTHERAPY ON THE PLASMATIC COAGULATION AND FIBRINOLYTIC SYSTEM IN LUNG CANCER PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643187.

Full text
Abstract:
Following the administration of cytostatic drugs, an increase in thromboembolic phenomena has been described in cancer patients. Such hemostatic alterations may be related to degree of hipercoa-gulability observed following chemotherapy, in comparison to previous levels. In terms of the fibrinolytic system, however, no - clearly defined alterations have been detected. We studied the - changes in plasmatic coagulation and fibrinolysis in 40 patients with non-operable stage III and IV lung cancer (30 epidermoid - ad 10 microcytic neoplasms) following cytostatic chemotherapy. Two studies were done on each patient, i.e., one at the time of diagnosis, -and the other 48 hours after completing the first chemotherapeutic cycle. The results show significant (p 0,05) post-chemotherapy increases in fibrinopeptide A (FPA) levels (pre: 2.95 ± 3.98, post: 8.15 ± 9.40 ng/ml), as well as a decrease in fibrinolytic activity reflected by a drop (p 0.01) in functional tissue plasminogen activator (t-PA) (pre: 1.53 ± 1.66, post: 0.91 ± 0.95 ng/ml). Morever, a tendency towards reduced euglobulinic precipitate lysis on fibrin agar was observed (pre: 122.8 ± 85.7, post: 105 ± 71.5%). The other parameters evaluated, i.e., antithrombin III, plasminogen immunologic t-PA and functional PA inhibitor - (PAI) showed no significant changes.We have also studied the potential accumulative effect of three chemotherapy courses and the results were compared to the situation at the time of diagnosis. A significant increase p 0.01 in functional PAI has been observed (pre: 1.85 ± 2.38, post: 5.41 ± 3.74 U/ml). The possible participation of tumor mass in the elevation of these parameter was considered: but no relation betwen tumor mass and increase PAI have been detected.Chemotherapy is apparently capable of conditioning a decrease in fibrinolytic activity in these cancer patients, this could be related to the enhanced tendency of these patients to developing - thromboembolic phenomena following cytostatic chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Chemotherapy of cancer"

1

Hait, William N. Genetic Susceptibility to Cancer Chemotherapy in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2001. http://dx.doi.org/10.21236/ada398401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hait, William. Genetic Susceptibility to Cancer Chemotherapy in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2000. http://dx.doi.org/10.21236/ada396563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Halt, William N. Genetic Susceptibility to Cancer Chemotherapy in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada382957.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hamilton, Andrew D. Growth Factor Antagonism in Breast Cancer Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2001. http://dx.doi.org/10.21236/ada395180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hamilton, Andrew D. Growth Factor Antagonism in Breast Cancer Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada406198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hamilton, Andrew. Growth Factor Antagonism in Breast Cancer Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada391066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jiang, Hongmei. Nanog, Cancer Stem Cells, and Resistance to Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, March 2014. http://dx.doi.org/10.21236/ada603912.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jiang, Hongmei. Nanog, Cancer Stem Cells, and Resistance to Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada594699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Luduena, Richard. Nuclear Tubulin: A Novel for Breast Cancer Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada392981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jiang, Hongmei. Nanog, Cancer Stem Cells, and Resistance to Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, September 2011. http://dx.doi.org/10.21236/ada554214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Chemotherapy of cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography